Citation: | LIU Yong, ZHANG Lianghong, LI Wenbao, MU Shengjun, ZHAO Xuedong, LI Qin, LI Baodong. Effect of tirofiban combined with oxiracetam on acute anterior circulation progressive cerebral infarction[J]. Journal of Clinical Medicine in Practice, 2025, 29(1): 107-111. DOI: 10.7619/jcmp.20244069 |
To investigate the effect of tirofiban combined with oxiracetam on acute anterior circulation progressive cerebral infarction.
A total of 171 patients with acute anterior circulation progressive cerebral infarction from October 2022 to January 2024 were enrolled and randomly divided into three groups using a random number table. The control group of 57 patients received conventional treatment, the observation group A received tirofiban in addition to conventional treatment, and the observation group B received oxiracetam on the basis of observation group A's treatment. The effectiveness indicators [including the rates of neurological improvement and neurological deterioration at 14 days after treatment, the rate of good prognosis and modified Rankin Scale (MRS) scores at 90 days after treatment, as well as the National Institutes of Health Stroke Scale (NIHSS) scores at 7 and 14 days after treatment and their differences from baseline], cognitive function [assessed using the Montreal Cognitive Assessment (MOCA)], and safety indicators (incidence rates of symptomatic intracranial hemorrhage, fatal intracranial hemorrhage, and mortality at 90 days after treatment) were compared among the three groups.
There were no statistically significant differences in the rates of neurological improvement and neurological deterioration at 14 days after treatment, the rate of good prognosis, and MRS scores at 90 days after treatment among the three groups (P>0.05). There were statistically significant differences in NIHSS scores between baseline and 7 and 14 days after treatment in all three groups (P < 0.05), and the differences in NIHSS scores from baseline at the above time points were higher in observation group B than in observation group A and the control group (P < 0.05). There were no statistically significant differences in MOCA scores among the three groups before treatment (P>0.05); however, the MOCA scores in the observation group B were higher than those in observation group A and the control group at 14, 30, and 90 days after treatment (P < 0.05). There were no statistically significant differences in the incidence rates of symptomatic intracranial hemorrhage, fatal intracranial hemorrhage, and mortality at 90 days after treatment among the three groups (P>0.05).
Tirofiban combined with oxiracetam can improve cognitive function in patients with acute anterior circulation progressive cerebral infarction without increasing the risk of hemorrhage, and has better prognosis.
[1] |
YU W J, YANG J J, LIU L L, et al. The value of diffusion weighted imaging in predicting the clinical progression of perforator artery cerebral infarction[J]. Neuroimage Clin, 2022, 35: 103117. doi: 10.1016/j.nicl.2022.103117
|
[2] |
欧吐红, 加曼·沙俄, 董娜. 急性脑梗死早期进展相关危险因素的临床研究分析[J]. 临床医药文献电子杂志, 2020, 7(84): 30-31.
|
[3] |
RODRIGUEZ-CALIENES A, BUSTAMANTE-PAYTAN D, CAMACHO-CABALLERO K, et al. Single-center experience with endovascular treatment of cerebral arteriovenous malformations with intent to cure in pediatric patients[J]. Childs Nerv Syst, 2022, 38(2): 343-351. doi: 10.1007/s00381-021-05376-5
|
[4] |
HUANG H Y, ZHANG S, DU H, et al. Effect of Clopidogrel combined with aspirin in the treatment of acute progressive cerebral infarction: a retrospective single-center analysis[J]. Pak J Med Sci, 2024, 40(5): 891-895.
|
[5] |
KARATHANOS A, LIN Y F, DANNENBERG L, et al. Routine glycoprotein IIb/IIIa inhibitor therapy in ST-segment elevation myocardial infarction: AMeta-analysis[J]. Can J Cardiol, 2019, 35(11): 1576-1588. doi: 10.1016/j.cjca.2019.05.003
|
[6] |
董漪, 桂莉, 郑华光, 等. 2019 AHA/ASA急性缺血性卒中早期管理指南全面解读(下)[J]. 中国卒中杂志, 2020, 15(1): 63-74. doi: 10.3969/j.issn.1673-5765.2020.01.010
|
[7] |
中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志, 2018, 51(9): 666-682. doi: 10.3760/cma.j.issn.1006-7876.2018.09.004
|
[8] |
全国第四届脑血管病学术会议. 脑卒中患者临床神经功能缺损程度评分标准(1995)及各类脑血管疾病诊断要点[J]. 中华神经科杂志, 1996, 29(6): 379-383. doi: 10.3760/j.issn:1006-7876.1996.06.006
|
[9] |
RYU W S, HONG K S, JEONG S W, et al. Association of ischemic stroke onset time with presenting severity, acute progression, and long-term outcome: a cohort study[J]. PLoS Med, 2022, 19(2): e1003910. doi: 10.1371/journal.pmed.1003910
|
[10] |
许方彧, 宋彦, 刘彦荣. 急性脑梗死患者疾病进展与血管基础的关系研究[J]. 国际医药卫生导报, 2022, 28(19): 2682-2685. doi: 10.3760/cma.j.issn.1007-1245.2022.19.004
|
[11] |
黄震, 由金玉. 心脏外科手术后并发脑梗死的临床特征及影响因素[J]. 实用临床医药杂志, 2021, 25(11): 68-71. doi: 10.7619/jcmp.20210852
|
[12] |
苏燕, 刘凯, 杜苑苑, 等. 急性脑梗死患者miR-184表达水平与病情严重程度及炎性因子的相关性研究[J]. 中华全科医学, 2023, 21(7): 1093-1096.
|
[13] |
吕敏, 陈颖聪, 温慧军. 脑梗死偏瘫患者抑郁与认知功能障碍程度的关系及其相关影响因素研究[J]. 空军军医大学学报, 2023, 44(11): 1082-1086.
|
[14] |
KITAZONO T, KAMOUCHI M, MATSUMARU Y, et al. Efficacy and safety of prasugrel vs clopidogrel in thrombotic stroke patients with risk factors for ischemic stroke recurrence: a double-blind, phase III study (PRASTRO-Ⅲ)[J]. J Atheroscler Thromb, 2023, 30(3): 222-236. doi: 10.5551/jat.63473
|
[15] |
BHATIA K, JAIN V, AGGARWAL D, et al. Dual antiplatelet therapy versus aspirin in patients with stroke or transient ischemic attack: meta-analysis of randomized controlled trials[J]. Stroke, 2021, 52(6): e217-e223.
|
[16] |
DU N, WANG L X, LIU Y L, et al. Effect of tirofiban in treating patients with progressive ischemic stroke[J]. Eur Rev Med Pharmacol Sci, 2022, 26(6): 2098-2105.
|
[17] |
TANG X Y, LI R J. Effects of Tirofiban in Patients with Acute Myocardial Infarction and Diabetes Mellitus undergoing Primary Percutaneous Coronary Intervention[J]. Curr Vasc Pharmacol, 2024, 22(1): 41-49. doi: 10.2174/0115701611251882231012080210
|
[18] |
PENG R, LI F. The clinical efficacy of tirofiban combined with ticagrelor and aspirin in treating acute myocardial infarction by percutaneous coronary intervention and its effect on patients' cardiac function[J]. J Healthc Eng, 2022, 2022: 4708572.
|
[19] |
LI L, YANG B, DMYTRIW A A, et al. Correlations between intravascular pressure gradients and cerebral blood flow in patients with symptomatic, medically refractory, anterior circulation artery stenosis: an exploratory study[J]. J Neurointerv Surg, 2024, 16(6): 608-614. doi: 10.1136/jnis-2023-020144
|
[20] |
ZHAO W B, LI S J, LI C H, et al. Effects of tirofiban on neurological deterioration in patients with acute ischemic stroke: a randomized clinical trial[J]. JAMA Neurol, 2024, 81(6): 594-602. doi: 10.1001/jamaneurol.2024.0868
|
[21] |
HUANG Y Y, CHEN S D, LENG X Y, et al. Post-stroke cognitive impairment: epidemiology, risk factors, and management[J]. J Alzheimers Dis, 2022, 86(3): 983-999.
|
1. |
曾林,史易晗,孙荣鑫,张磊,高健,姜侃. 深静脉血栓形成的多组学研究进展. 骨科临床与研究杂志. 2024(02): 125-128 .
![]() | |
2. |
乔琛琛,梁云龙. ABO血型对达比加群酯治疗非瓣膜性房颤效果的影响. 实用临床医药杂志. 2023(23): 63-67 .
![]() |